Enhanced soluble thrombomodulin, t-PA and u-PA concentrations caused by short-term endothelial damage during percutaneous cardiac catheterisation

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 47-49

  Vielhaber, H ^a,b   Kehl, H G ^a   Kececioglu, D ^a   Vogt, J ^a   Nowak Gottl U ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADOLESCENT; CELL DAMAGE; CHILD; CONFERENCE PAPER; ENDOTHELIUM CELL; HEART CATHETERIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029855530     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80046-4     Document Type: Conference Paper

References (13)

1. Takano S, Kimura S, Ohodama S, Aoki N. Plasma thrombomodulin in health and disease. Blood 1990; 79: 837-838
2. Wada H, Ohiwa M, Kaneko T, et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Haematol 1992; 39: 20-24
3. Iwashima Y, Sato T, Watanabe K, et al. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-988
4. Hoshi K, Inoue T, Kakoi H, et al. Plasma thrombomodulin levels in coronary sinus blood in patients with artery disease. Blood Coagulation & Fibrinolysis 1995; 6: 129-132
5. Ohdama S, Yoshizawa Y, Kubota T, Aoki N. Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus. Int J Cardiol 1994; 47/2: S1-S6
6. Van den Berg M, Boers GHJ, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-181
7. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FABS 1995; 9: 946-955
8. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost 1979; 41: 365-383
9. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulating levels of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in subjects with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-1745
10. Ridker PM, Vaughan DE, Stampfer MK, Manson JE, Hennekens D. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
11. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan D. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943
12. Vielhaber H, Kohlhase B, Koch HG, et al. Flush heparin during cardiac catheterisation prevents long-term coagulation activation in children without APC-resistance-preliminary results. Thromb Res 1996; 81: 651-656
13. Nowak-Göttl U, Koch HG, Ashka I, et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996; 92: 992-998